Q BioMed (Q BioMed) Pre-Tax Income : $-0.49 Mil (TTM As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Q BioMed's pretax income for the three months ended in Feb. 2023 was $-0.72 Mil. Its pretax income for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.49 Mil. Q BioMed's pretax margin was %.

Q BioMed Pre-Tax Income Historical Data

The historical data trend for Q BioMed's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Pre-Tax Income Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Pre-Tax Income

Get a 7-Day Free Trial

-9.27

-10.28

-13.49

-8.24

-2.05

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
Pre-Tax Income	Get a 7-Day Free Trial															-2.29	-1.27	-0.80	2.30	-0.72

Competitive Comparison of Q BioMed's Pre-Tax Income

For the Biotechnology subindustry, Q BioMed's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Q BioMed's Pre-Tax Income falls into.

Q BioMed Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Q BioMed's Pretax Income for the fiscal year that ended in Nov. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.446	+	2.778	+	-1.384	+	0	+	0
	=	-2.05

Q BioMed's Pretax Income for the quarter that ended in Feb. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.445	+	0	+	-0.277	+	0	+	0
	=	-0.72

Pre-Tax Income for the trailing twelve months (TTM) ended in Feb. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49 Mil.

Q BioMed (OTCPK:QBIO) Pre-Tax Income Explanation

Q BioMed's Pretax Margin for the quarter that ended in Feb. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.722	/	0
	=	%

Q BioMed Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Q BioMed's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1